You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 9,919,057


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,919,057
Title:Compounds comprising self-immolative group
Abstract: Provided are compounds comprising a self-immolative group, and the compounds comprising a self-immolative group according to the present invention may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.
Inventor(s): Kim; Yong Zu (Daejeon, KR), Park; Tae Kyo (Daejeon, KR), Woo; Sung Ho (Daejeon, KR), Kim; Sun Young (Daejeon, KR), Cho; Jong Un (Daejeon, KR), Jung; Doo Hwan (Daejeon, KR), Yang; Jeon (Daejeon, KR), Min; Ji Young (Daejeon, KR), Lee; Hyang Sook (Daejeon, KR), Park; Yun Hee (Daejeon, KR), Ryu; Jeong Hee (Daejeon, KR), Oh; Kyu Man (Daejeon, KR), Oh; Yeong Soo (Daejeon, KR), Chae; Jeiwook (Daejeon, KR), Song; Ho Young (Daejeon, KR), Chung; Chul-Woong (Daejeon, KR)
Assignee: LegoChem Biosciences, Inc. (Daejeon, KR)
Application Number:14/865,778
Patent Claims:1. A compound represented by the following Chemical Formula 1: ##STR00032## G is a glucuronic acid moiety or ##STR00033## wherein R.sub.3 is hydrogen or a carboxyl protecting group, and each R.sub.4 is independently hydrogen or a hydroxyl protecting group; A is an antibody, B is an active agent; W is --C(O)--, --C(O)NR'--, --C(O)O--, --SO.sub.2NR'--, --P(O)R''NR'--, --SONR'--, or --PO.sub.2NR'--, in each case where the C(O), S, or P is directly bound to the phenyl ring, and R' and R'' are each independently hydrogen, (C.sub.1-C.sub.8)alkyl, (C.sub.3-C.sub.8)cycloalkyl, (C.sub.1-C.sub.8)alkoxy, (C.sub.1-C.sub.8)alkylthio, mono- or di-(C.sub.1-C.sub.8)alkylamino, (C.sub.3-C.sub.20)heteroaryl or (C.sub.6-C.sub.20)aryl; Z is hydrogen, (C.sub.1-C.sub.8)alkyl, halogen, cyano, or nitro; n is an integer of 1 to 3, and when n is an integer of 2 or more, each of the Z(s) are the same as or different from each other; wherein either: A) L is an alkylene chain having 1 to 50 carbon atoms and satisfies at least one of the following (i) to (iv): (i) the alkylene includes at least one unsaturated bond, (ii) the alkylene includes at least one heteroarylene, (iii) at least one carbon atom of the alkylene is replaced with one or more hetero atoms selected from nitrogen (N), oxygen (O), and sulfur (S), and P (iv) the alkylene is substituted with one or more alkyls having 1 to 20 carbon atoms; or B) L includes at least one isoprenyl derivative unit represented by the following Chemical Formula A, which is recognized by an isoprenoid transferase ##STR00034## and R.sub.1 and R.sub.2 are each independently hydrogen, (C.sub.1-C.sub.8)alkyl, or (C.sub.3-C.sub.8)cycloalkyl.

2. The compound of claim 1, wherein G is ##STR00035## R.sub.3 is hydrogen or a carboxyl protecting group, and R.sub.4(s) are each independently hydrogen or a hydroxyl protecting group.

3. The compound of claim 1, wherein W is --C(O)--, --C(O)NR'--, or --C(O)O--.

4. The compound of claim 1, wherein the linker L is an alkylene having 1 to 50 carbon atoms and satisfies at least one of the following (i) to (iv): (i) the alkylene includes at least one unsaturated bond, (ii) the alkylene includes at least one heteroarylene, (iii) at least one carbon atom of the alkylene is replaced with one or more hetero atoms selected from nitrogen (N), oxygen (O), and sulfur (S), and (iv) the alkylene is substituted with one or more alkyls having 1 to 20 carbon atoms.

5. The compound of claim 1, wherein the linker L includes at least one isoprenyl derivative unit represented by the following Chemical Formula A, which is recognized by an isoprenoid transferase: ##STR00036##

6. The compound of claim 5, wherein the linker L further includes a binding unit represented by Chemical Formula B, C, D, or E: ##STR00037## L.sub.1 is a single bond or alkylene having 1 to 30 carbon atoms; R.sub.11 is hydrogen or alkyl having 1 to 10 carbon atoms; and L.sub.2 is alkylene having 1 to 30 carbon atoms.

7. The compound of claim 6, wherein the linker L further includes a connection unit represented by the following Chemical Formula F or G: --(CH.sub.2).sub.r(V(CH.sub.2).sub.p).sub.q-- [Chemical Formula F] --(CH.sub.2CH.sub.2X).sub.w-- [Chemical Formula G] V is a single bond, --O--, --S--, --NR.sub.21--, --C(O)NR.sub.22--, --NR.sub.23C(O)--, --NR.sub.24SO.sub.2--, or --SO.sub.2NR.sub.25--; X is --O--, (C.sub.1-C.sub.8)alkylene, or --NR.sub.21--; R.sub.21 to R.sub.25 are each independently hydrogen, (C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)alkyl(C.sub.6-C.sub.20)aryl, or (C.sub.1-C.sub.6)alkyl(C.sub.3-C.sub.20)heteroaryl; r is an integer of 1 to 10; p is an integer of 0 to 10; q is an integer of 1 to 10; and w is an integer of 1 to 10.

8. The compound of claim 1, wherein the antibody comprises an amino acid motif recognizable by an isoprenoid transferase.

9. The compound of claim 8, wherein the antibody further comprises a spacer unit comprising an amino acid, an oligopeptide, or a polypeptide between the antibody and the amino acid motif.

10. The compound of claim 8, wherein the antibody is covalently bonded to the linker L through the amino acid motif.

11. The compound of claim 10, wherein the amino acid motif is at a C-terminus of the antibody.

12. The compound of claim 11, wherein the C-terminus of the antibody is a C-terminus of a light chain or a heavy chain of the antibody.

13. The compound of claim 8, wherein the isoprenoid transferase is farnesyl protein transferase (FTase) or geranylgeranyl transferase (GGTase).

14. The compound of claim 1, wherein the antibody is selected from intact polyclonal antibodies, intact monoclonal antibodies, antibody fragments, single chain Fv (scFv) mutants, multispecific antibodies, bispecific antibodies, chimeric antibodies, humanized antibodies, human antibodies, fusion proteins including an antigen determination portion of an antibody, and other modified immunoglobulin molecules including an antigen recognition site.

15. The compound of claim 14, wherein the antibody is selected from muromonab-CD3, abciximab, rituximab, daclizumab, palivizumab, infliximab, trastuzumab, etanercept, basiliximab, gemtuzumab ozogamicin, alemtuzumab, ibritumomab tiuxetan, adalimumab, alefacept, omalizumab, efalizumab, tositumomab-I.sup.131, cetuximab, bevacizumab, natalizumab, ranibizumab, panitumumab, eculizumab, rilonacept, certolizumab pegol, romiplostim, belimumab, anti-CD20, tocilizumab, atlizumab, mepolizumab, pertuzumab, tremelimumab, ticilimumab, inotuzumab ozogamicin, aflibercept, catumaxomab, pregovomab, motavizumab, efumgumab, raxibacumab, and veltuzumab.

16. The compound of claim 14, wherein the antibody is a monoclonal antibody.

17. The compound of claim 1, wherein the active agent is a drug, a toxin, an affinity ligand, a detection probe, or a combination thereof.

18. The compound of claim 1, wherein the active agent is an immunomodulatory compound, an anticancer agent, an antiviral agent, an antibacterial agent, an antifungal agent, an antiparasitic agent, or a combination thereof.

19. The compound of claim 8, wherein the amino acid motif is (G).sub.zCVIM (SEQ ID NO: 1) or (G).sub.zCVLL (SEQ ID NO: 2), G representing a glycine unit, and z being an integer of 0 to 20.

20. The compound of claim 19, selected from compounds having the following structures: ##STR00038## wherein: Z is hydrogen, (C.sub.1-C.sub.8)alkyl, halogen, cyano, or nitro; X is --O--, (C.sub.1-C.sub.8)alkylene, or --NR.sub.21--; R.sub.21 is hydrogen, (C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)alkyl(C.sub.6-C.sub.20)aryl, or (C.sub.1-C.sub.6)alkyl(C.sub.3-C.sub.20)heteroaryl; n is an integer of 1 to 3, and when n is an integer of 2 or more, each of the Z(s) are the same as or different from each other; r is an integer of 1 to 10; q is an integer of 1 to 10; w is an integer of 1 to 10; x is an integer of 0 to 10; g is an integer of 1 to 10; B is a drug having a structure selected from the following structures ##STR00039## ##STR00040## and y is an integer of 1 to 10.

Details for Patent 9,919,057

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Janssen Biotech, Inc. REOPRO abciximab Injection 103575 12/22/1994 ⤷  Try a Trial 2034-05-28
Genentech, Inc. RITUXAN rituximab Injection 103705 11/26/1997 ⤷  Try a Trial 2034-05-28
Novartis Pharmaceuticals Corporation SIMULECT basiliximab For Injection 103764 05/12/1998 ⤷  Try a Trial 2034-05-28
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.